Dr Douglas Richman | Director, Center for Aids Research
University of California San Diego

Dr Douglas Richman, Director, Center for Aids Research, University of California San Diego

Dr. Richman conducted research on influenza virus, herpesviruses and hemorrhagic fever viruses before focusing on HIV in the 1980s. HIV drug resistance was originally recognized in his laboratory. His lab also identified the latent HIV reservoir as the obstacle to cure with antiretroviral therapy, and the neutralizing antibody response as the selection pressure for continuing neutralization escape and envelope evolution within HIV infected individuals. In addition to his continuing interest in HIV treatment and drug resistance, his research interests have focused on HIV pathogenesis, especially the latent HIV reservoir.  ( https://en.wikipedia.org/wiki/Douglas_Richman )


WVIC/WAC Day 1 - Nov 29 @ 16:50

Are long-acting ARTs the future of HIV prevention and treatment?

  • How can we improve the half-life of long-acting ARTs?
  • How can we enhance the uptake/usage of long-acting formulations?
  • What are the implementation challenges for therapies?
  • What are the key policy issues for these types of therapies?
  • Why can long-acting injectable therapies be difficult to access in LMIC?
last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard


For sponsorship and exhibition opportunities:
Thomas Hall